Privately held and co-founded by immunologists Nejat Egilmez and Richard Bankert, Therapyx Inc. is a Buffalo biotechnology start-up developing immune-based medicines. The company is known for its ExStaM platform, which uses microparticles to deliver protein therapeutics locally and over time for serious diseases.
FDA Orphan Drug Designation for PCX12 — Malignant Glioma
compliance_program
FDA Orphan Drug Designation for PCX12 — Pancreatic Cancer
compliance_program
LifePulse CorporationLifePulse Corporation develops and manufactures its US-engineered Intellipulse® platform to deliver therapeutics directly into cells, with a focus on targeted oncology in human and veterinary medicine. Founded by Gary Strange, the Tampa Bay company builds on more than three decades of research, $35 million in non-dilutive funding, and over 100 issued patents. Its animal-health division has treated hundreds of dogs, cats, and horses since 2022, while its human-health program is advancing toward pancreatic-tumor trials.NEW YORK, NY
Innovative Cellular TherapeuticsHeadquartered in Rockville, Innovative Cellular Therapeutics is a private clinical-stage biotechnology company developing cellular immunotherapies for solid tumors. Its proprietary CoupledCAR® platform underpins individually made CAR-T therapies, including the lead GCC19CART program being studied for relapsed or refractory metastatic colorectal cancer. Founded by Larry Lei Xiao and Zoe Zhao Wu, ICT combines more than 20 years of stem-cell, cell-therapy and gene-editing experience with FDA cellular-therapy review expertise.ROCKVILLE, MD
TechnoVax IncFounded in 2004, privately held TechnoVax is a New York metro-area biotechnology company developing viral vaccines through a cell-based virus-like particle platform. Its near-clinical-stage work centers on vaccine candidates for influenza and RSV, including an inhaled powder approach developed with a pulmonary drug-delivery partner. The company also provides biological products and collaborative research services for vaccine, diagnostic, and research applications.ELMSFORD, NY
Incintas Therapeutics, IncFounded by a team that includes business leaders, physicians and reproductive-science specialists, Incintas Therapeutics focuses on a stubborn problem in assisted reproduction: embryos that fail to implant. The company is developing a localized, time-released progesterone therapy for fertility-treatment patients, intended to extend the uterus’s brief period of receptivity.ATGLEN, PA